


The invention relates to medicine, in particular to pharmacology and infectious diseases, namely to compositions and unit dosage forms for the treatment of hepatitis C virus infection.

The pharmaceutical composition comprises:

a) about 25% to about 35% w/w of crystalline form having the structure:



(GS-7977); and

b) at least one pharmaceutically acceptable excipient, wherein the crystalline GS-7977 has HRPD 2 θ -reflections ($^{\circ}$) at about: 6.1 and 12.7.

According to the invention, also disclosed are methods of treating subjects infected with hepatitis C virus comprising administering to the subjects for a time period effective amounts of GS-7977 and of interferon-free ribavirin.

Claims: 37

Fig.: 3